Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Rating of “Hold” from Analysts

Cara Therapeutics, Inc. (NASDAQ:CARA) has earned an average rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $27.84.

Separately, StockNews.com assumed coverage on shares of Cara Therapeutics in a report on Wednesday, January 8th. They issued a “sell” rating for the company.

Cara Therapeutics Trading Up 0.8 %

Shares of CARA opened at $5.01 on Tuesday. Cara Therapeutics has a 12-month low of $2.71 and a 12-month high of $13.80. The firm has a 50-day moving average price of $4.97 and a 200 day moving average price of $4.07. The firm has a market capitalization of $22.90 million, a P/E ratio of -0.24 and a beta of 0.50.

Institutional Investors Weigh In On Cara Therapeutics

A number of institutional investors have recently made changes to their positions in CARA. FMR LLC increased its position in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Cara Therapeutics in the third quarter valued at approximately $29,000. Rockefeller Capital Management L.P. acquired a new position in shares of Cara Therapeutics in the fourth quarter valued at approximately $953,000. Curi RMB Capital LLC acquired a new position in shares of Cara Therapeutics in the fourth quarter valued at approximately $277,000. Finally, Shay Capital LLC acquired a new position in shares of Cara Therapeutics in the fourth quarter valued at approximately $524,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.